Technology
Health
Biotechnology

Voyager Therapeutics

$18.09
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.

-$0.32 (-1.74%) Today
$0.00 (0.00%) After Hours

Why Robinhood?

You can buy or sell VYGR and other stocks, options, ETFs, and crypto commission-free!

About

Voyager Therapeutics, Inc. operates as a clinical-stage gene therapy company, which develops treatments for patients suffering from central nervous system. Its pipeline of gene theraphy programs include VY-AADC, VY-SOD101, VY-HTT01, VY-FXN01, Tau Program, and VY-NAV01. Read More The company was founded by Guangping Gao, Mark A. Kay, Krystof Bankiewicz and Phillip Zamore in June 2013 and is headquartered in Cambridge, MA.

Employees
123
Headquarters
Cambridge, Massachusetts
Founded
2013
Market Cap
595.84M
Price-Earnings Ratio
Dividend Yield
0.00
Average Volume
424.20K
High Today
$18.55
Low Today
$17.91
Open Price
$18.19
Volume
166.43K
52 Week High
$24.24
52 Week Low
$7.76

Collections

Technology
Health
Biotechnology
Therapy
Medical
2015 IPO
US
North America

News

MarketBeatFeb 28

Stock Price, News, & Analysis for Voyager Therapeutics

Voyager Therapeutics, Inc., a clinical-stage gene therapy company, focuses on the development of treatments for patients suffering from severe neurological diseases. The company's lead clinical candidate is the VY-AADC, which is in open-label Phase 1b clinical trials for the treatment of advanced Parkinson's disease. Its preclinical programs comprise VY-SOD101 for a monogenic form of amyotrophic lateral sclerosis; VY-HTT01 for Huntington's disease; VY-FXN01 for Friedreich's ataxia; Tau program, for tauopath...

269
Yahoo FinanceFeb 25

AbbVie Extends Deal With Voyager to Make Parkinson's Drugs

AbbVie (ABBV) expands its collaboration with Voyager Therapeutics to develop potential vectorized antibodies for Parkinson's disease (PD) and other synucleinopathies.

536
MarketWatchFeb 22

Voyager Therapeutics stock soars after AbbVie collaboration potentially valued at over $1 billion

Shares of Voyager Therapeutics Inc. VYGR, -1.93% ran up 14.2% in premarket trade Friday, after the gene therapy company and AbbVie Inc. ABBV, -1.55% announced a collaboration to develop antibodies to treat Parkinson's disease. AbbVie's stock was still inactive ahead of the open. Under terms of the collaboration, Voyager will receive $65 million upfront and up to $245 million in preclinical and phase 1 option payments, as well as up to an additional $728 million in potential milestone payments and royalties....

1,448

Earnings

-$0.89
-$0.65
-$0.40
-$0.16
Q2 2017
Q3 2017
Q4 2017
Q1 2018
Q2 2018
Q3 2018
Q4 2018
Q1 2019
Estimated
Actual
Expected May 9, After Hours
All investments involve risk and the past performance of a security, or financial product does not guarantee future results or returns. Securities offered through Robinhood Financial LLC, member FINRA/SIPC. To learn more about the information provided on this page, please see our Web Disclosures.